Clinical Update: AIDS Research Marches On
A short discussion of the state of HIV/AIDS research, including drug and vaccine development, reversing AIDS' destructive process, and new studies in this area.
You may also be interested in...
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
Abbott Laboratories' Norvir (ritonavir) set a record early in March: the FDA reviewed and approved the protease inhibitor for use alone or in combination therapy as a treatment for late-stage AIDS just 72 days after filing.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.